Higher-level pathway objectives of epigenetic therapy: a solution to the p53 problem in cancer
V Velcheti, T Radivoyevitch… - American Society of …, 2017 - ascopubs.org
Searches for effective yet nontoxic oncotherapies are searches for exploitable differences
between cancer and normal cells. In its core of cell division, cancer resembles normal life …
between cancer and normal cells. In its core of cell division, cancer resembles normal life …
The current landscape of early drug development for patients with sarcoma
Until recently, advancements in the treatment of patients with adult soft tissue sarcomas
have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better …
have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better …
[HTML][HTML] 五例白血病全外显子测序结果分析
康娅, 王梦昌 - 实用肿瘤杂志, 2020 - html.rhhz.net
目的探讨二代测序技术用于白血病骨髓标本全外显子基因测序检测发现基因突变的价值.
方法获取5 例初发白血病骨髓标本, 采用二代测序技术行全外显子测序检测并确定致病易感突变 …
方法获取5 例初发白血病骨髓标本, 采用二代测序技术行全外显子测序检测并确定致病易感突变 …
A data fusion approach for learning transcriptional Bayesian networks in chronic leukemia
E Sauta - 2018 - iris.unipv.it
The increasing availability of omics data has caused an important paradigmatic shift in
scientific research from case-based studies towards large scale data-driven research. The …
scientific research from case-based studies towards large scale data-driven research. The …
Bridging the Gap Between Our Understanding of AML Pathogenesis and the Development of Targeted Therapies
M Tavakkoli - 2014 - academiccommons.columbia.edu
Bridging the Gap Between Our Understanding of AML Pathogenesis and the Development of
Targeted Therapies Montreh Tavakkoli Submitted in partial fulfillment of the requirements for the …
Targeted Therapies Montreh Tavakkoli Submitted in partial fulfillment of the requirements for the …